Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 28NSCLC 4Brain Neoplasms 4Lung Neoplasms 3Pancreatic Neoplasms 2EGF-R Positive Non-Small Cell Lung Cancer 2Adenocarcinoma 2Squamous Cell Carcinoma of Lung 1Plasma EGFR Mutation-positive Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Non-Small-Cell Lung 1Neoplasms, Second Primary 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 51Gemcitabine 24Radiotherapy, Intensity-Modulated 21Docetaxel 20Fluorouracil 15camrelizumab 12Drug Therapy 11Radiotherapy 10toripalimab 8Chemoradiotherapy 8Capecitabine 8apatinib 7Induction Chemotherapy 7nimotuzumab 6endostar protein 6Endostatins 6sintilimab 5nedaplatin 5Bevacizumab 5fludarabine 4Cyclophosphamide 4spartalizumab 3fludarabine phosphate 3cisplatin-guanosine adduct 3SSRP1 protein, human 3Paclitaxel 3Injections 3Endoscopy 3tislelizumab 2Vitamin B 12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nasopharyngeal Carcinoma × icotinib × Clear all
NCT02328261 2014-12-31

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
66 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡